BR112021021921A2 - Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica - Google Patents

Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica

Info

Publication number
BR112021021921A2
BR112021021921A2 BR112021021921A BR112021021921A BR112021021921A2 BR 112021021921 A2 BR112021021921 A2 BR 112021021921A2 BR 112021021921 A BR112021021921 A BR 112021021921A BR 112021021921 A BR112021021921 A BR 112021021921A BR 112021021921 A2 BR112021021921 A2 BR 112021021921A2
Authority
BR
Brazil
Prior art keywords
agent
treating
preventing
metabolic disease
methods
Prior art date
Application number
BR112021021921A
Other languages
English (en)
Inventor
Anindya Widjaja Anissa
Kumars Singh Brijesh
Sebastian Schaefer
Alexander Cook Stuart
Original Assignee
Nat Univ Singapore
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906291.8A external-priority patent/GB201906291D0/en
Priority claimed from GBGB2001013.8A external-priority patent/GB202001013D0/en
Priority claimed from GBGB2001896.6A external-priority patent/GB202001896D0/en
Priority claimed from GBGB2002030.1A external-priority patent/GB202002030D0/en
Application filed by Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Nat Univ Singapore
Publication of BR112021021921A2 publication Critical patent/BR112021021921A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica. são divulgados métodos de tratamento e prevenção de doenças metabólicas através da inibição da sinalização mediada por interleucina 11 (il-11), bem como agentes para uso em tais métodos.
BR112021021921A 2019-05-03 2020-05-01 Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica BR112021021921A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1906291.8A GB201906291D0 (en) 2019-05-03 2019-05-03 Treatment and prevention of metabolic diseases
GBGB1906597.8A GB201906597D0 (en) 2019-05-03 2019-05-10 Treatment and prevention of metabolic diseases
GBGB2001013.8A GB202001013D0 (en) 2020-01-24 2020-01-24 Treatment and prevention of metabolic diseases
GBGB2001896.6A GB202001896D0 (en) 2020-02-12 2020-02-12 Treatment and prevention of metabolic diseases
GBGB2002030.1A GB202002030D0 (en) 2020-02-14 2020-02-14 Treatment and prevention of metabolic diseases
PCT/EP2020/062193 WO2020225147A1 (en) 2019-05-03 2020-05-01 Treatment and prevention of metabolic diseases

Publications (1)

Publication Number Publication Date
BR112021021921A2 true BR112021021921A2 (pt) 2021-12-28

Family

ID=73051262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021921A BR112021021921A2 (pt) 2019-05-03 2020-05-01 Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica

Country Status (12)

Country Link
US (2) US11813311B2 (pt)
EP (1) EP3962936A1 (pt)
JP (1) JP2022531591A (pt)
KR (1) KR20220050087A (pt)
CN (1) CN114364693A (pt)
AU (1) AU2020268619A1 (pt)
BR (1) BR112021021921A2 (pt)
CA (1) CA3146344A1 (pt)
CL (1) CL2021002878A1 (pt)
MX (1) MX2021013356A (pt)
TW (1) TW202108606A (pt)
WO (1) WO2020225147A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113041248A (zh) * 2021-04-26 2021-06-29 北京亿药科技有限公司 Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用
EP4376948A1 (en) * 2021-07-26 2024-06-05 Boehringer Ingelheim International GmbH Treatment and prevention of alcoholic liver disease
CN114081882B (zh) * 2021-11-15 2023-01-10 中国科学院深圳先进技术研究院 一种a-fabp蛋白抑制剂及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
WO2009052588A1 (en) 2007-10-26 2009-04-30 Csl Limited Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP4219552A3 (en) 2013-02-07 2023-09-13 CSL Ltd. Il-11r binding proteins and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112017002637A2 (pt) 2014-08-11 2018-02-20 Ophthotech Corporation métodos para tratar ou prevenir condições oftalmológicas
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
MX2019007020A (es) 2016-12-16 2019-10-21 Singapore Health Serv Pte Ltd Anticuerpos il-11.
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
EP3962936A1 (en) 2022-03-09
CL2021002878A1 (es) 2022-10-07
WO2020225147A1 (en) 2020-11-12
US11813311B2 (en) 2023-11-14
JP2022531591A (ja) 2022-07-07
US20210177940A2 (en) 2021-06-17
TW202108606A (zh) 2021-03-01
CA3146344A1 (en) 2020-11-12
KR20220050087A (ko) 2022-04-22
CN114364693A (zh) 2022-04-15
MX2021013356A (es) 2022-03-11
AU2020268619A1 (en) 2021-12-16
US20240156913A1 (en) 2024-05-16
US20200384083A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
CL2020002737A1 (es) Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)
BR112021016613A2 (pt) Agente capaz de inibir a sinalização mediada por interleucina 11 (il-11), uso deste na fabricação de um medicamento e métodos
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
BR112018009311A8 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
BR112017024853A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
BR112018012022A2 (pt) ?composição, e, método para tratamento ou redução do risco de colestase intra-hepática?
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
UY38352A (es) Inhibidores de integrina alfavbeta6
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
BR112022002889A2 (pt) Método para tratar distrofia muscular tendo como alvo o gene lama1
BR112021010804A2 (pt) Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
MX2021000935A (es) Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico.
BR112017002166A2 (pt) terapias antibióticas de peptídeos derivados do búfalo d?água
BR112017022656A2 (pt) conservação in vitro de células terapêuticas